Skip to content

Collaborative Care for Depression and Diabetic Retinopathy in African Americans

Collaborative Care for Depression and Diabetic Retinopathy in African Americans

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02121340
Acronym
CC-DDR
Enrollment
40
Registered
2014-04-23
Start date
2014-05-31
Completion date
2018-12-31
Last updated
2019-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Retinopathy

Keywords

Depression, Health disparities, African American, Geriatric

Brief summary

In this feasibility/pilot study, we will develop, refine, and evaluate the feasibility of a novel mental health/ophthalmologic intervention called, Collaborative Care for Depression and Diabetic Retinopathy (CC-DDR), which aims to treat depression and lower HbA1C in older African Americans with mild-to-moderate diabetic retinopathy (DR) and comorbid depression.

Detailed description

The Specific Aims are: 1. To develop the CC-DDR treatment protocol. This will involve: 1. Creating an initial version of the CC-DDR treatment protocol. 2. Refining the protocol based on input from an expert panel with expertise in DR, depression, and culturally relevant interventions for diabetes in older African Americans. 3. Developing a tool to assess interventionist treatment adherence and competence. 2. To conduct an open trial of CC-DDR with 40 participants who have poorly controlled diabetes, depression, and mild or moderate DR. During this open trial we will: 1. Evaluate the feasibility of CC-DDR. 2. Refine the CC-DDR treatment protocol by incorporating feedback from participants, community health care workers (CHWs), ophthalmologists, and the expert panel. 3. Refine procedures for recruitment and retention, outcome assessment, monitoring treatment fidelity, CHW training and supervision, quality assurance, and study administration, based on input from investigators, CHWs, participants, and the expert panel. 4. Examine CC-DDR's impact on depression severity; diabetes self-management practices; HbA1C level; blood pressure; adherence to the ophthalmologist treatment plan; vision function; quality of life; and satisfaction with CC-DDR. 3. To complete a Manual of Procedures that characterizes all aspects of the planned efficacy trial of CC-DDR.

Interventions

BEHAVIORALBehavioral Activation

Sponsors

Wills Eye
CollaboratorOTHER
Thomas Jefferson University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. African-American race 2. age ≥ 65 years 3. type 2 diabetes 4. mild or moderate nonproliferative DR with or without macular edema 5. depressive symptoms (i.e., Patient Health Questionnaire-9 score ≥5) 6. HbA1C ≥ 7.0%

Exclusion criteria

1. treated proliferative DR 2. global cognitive impairment (i.e., Mini Mental Status score ≤ 20) 3. psychiatric diagnosis other than depression 4. treatment for depression started in the previous 3 months 5. life expectancy under 2 years

Design outcomes

Primary

MeasureTime frameDescription
Hemoglobin A1c12 monthsChange in hemoglobin A1c from baseline to 12 months

Other

MeasureTime frameDescription
Depression12 monthsImprovement in depressive symptoms from baseline to 12 months
Progression of diabetic retinopathyBaseline to 12 months
Diabetes self management12 monthsImprovement from baseline to 12 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026